Heat sensitivity of human parvovirus B19

被引:44
|
作者
Yunoki, M
Tsujikawa, M
Urayama, T
Sasaki, Y
Morita, M
Tanaka, H
Hattori, S
Takechi, K
Ikuta, K
机构
[1] Osaka Univ, Microbial Dis Res Inst, Dept Virol, Suita, Osaka 5650871, Japan
[2] Mitsubishi Pharma Corp, Div Pharmaceut Res, Prot Res Lab, Osaka, Japan
关键词
bioassay; parvovirus B19; plasma products; viral safety; virus inactivation;
D O I
10.1046/j.1423-0410.2003.00280.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives To date there has been no published report on a systematic evaluation of the heat sensitivity of human parvovirus B19 (B19) and the related safety of the plasma-derived fractionated products. In this study, we examined the heat sensitivity of B19 by using the infectivity assay with cultured cells. Materials and Methods The heat sensitivity of B19 was examined by measuring the reduction in viral infectivity titres after heating liquid containing B19 at 60 degreesC. Viral infectivity was assayed by detection of viral antigens or viral mRNA in infected cells. As a control, canine parvovirus (CPV) was also heat-treated. Results B19 displayed quite different inactivation kinetics to CPV when both were heated in liquid at 60 degreesC. In sharp contrast to the latter, B19 was rapidly inactivated within 1 h when the virus was suspended in 5% or 25% human serum albumin solution, phosphate-buffered saline, or complete medium. However, B19 appeared to be resistant to heat inactivation in liquid containing 60% sucrose. Conclusions The heat sensitivity of B19 in liquid was clearly different from that of CPV. Significantly, the efficiency to inactivate B19 and reduce its infectivity following heating in liquid was mainly affected by the composition of the solutions used for virus suspension.
引用
收藏
页码:164 / 169
页数:6
相关论文
共 50 条
  • [21] Parvovirus B19
    Bundesgesundheitsblatt, 1998, 41 (2): : 83 - 87
  • [22] miRNA and tropism of human parvovirus B19
    Berillo, Olga
    Khailenko, Vladimir
    Ivashchenko, Anatoly
    Perlmuter-Shoshany, Lior
    Bolshoy, Alexander
    COMPUTATIONAL BIOLOGY AND CHEMISTRY, 2012, 40 : 1 - 6
  • [23] HUMAN PARVOVIRUS (B19) AND ERYTHEMA INFECTIOSUM
    NUNOUE, T
    OKOCHI, K
    MORTIMER, PP
    COHEN, BJ
    JOURNAL OF PEDIATRICS, 1985, 107 (01): : 38 - 40
  • [24] DISEASES CAUSED BY THE HUMAN PARVOVIRUS B19
    PATTISON, JR
    ARCHIVES OF DISEASE IN CHILDHOOD, 1988, 63 (12) : 1426 - 1427
  • [25] PARVOVIRUS B19 AND HUMAN-DISEASE
    TOROK, TJ
    ADVANCES IN INTERNAL MEDICINE, VOL 37, 1992, 37 : 431 - 455
  • [26] Human parvovirus B19 and blood products
    Prowse, C
    Ludlam, CA
    Yap, PL
    VOX SANGUINIS, 1997, 72 (01) : 1 - 10
  • [27] NAKATANI ANTIGEN AND HUMAN PARVOVIRUS (B19)
    OKOCHI, K
    MORI, R
    MIYAZAKI, M
    COHEN, BJ
    MORTIMER, PP
    LANCET, 1984, 1 (8369): : 160 - 161
  • [28] Human parvovirus B19 and renal disease?
    Bleumink, GS
    Halma, C
    van Vliet, ACM
    de Jong, GMT
    van Bommel, EFH
    NETHERLANDS JOURNAL OF MEDICINE, 2000, 56 (04): : 163 - 165
  • [29] Seroepidemiology of human parvovirus B19 in Taiwan
    Lin, KH
    You, SL
    Chen, CJ
    Wang, CF
    Yang, CS
    Yamazaki, S
    JOURNAL OF MEDICAL VIROLOGY, 1999, 57 (02) : 169 - 173
  • [30] Parvovirus B19
    Burger, R
    Gerlich, W
    Gürtler, L
    Heiden, M
    Kretschmer, V
    Lefèvre, H
    Löwer, J
    Montag-Lessing, T
    Neumann, R
    Pauli, G
    Seitz, R
    Schlenkrich, U
    Werner, E
    Illkommen, HW
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2005, 32 (3-4) : 121 - 126